ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The persistence of attention deficit hyperactivity disorder (ADHD) into adolescence and adulthood has now been accepted as a clinical entity. The rate of prevalence among adults is assumed to be from 2% to 4%. With increasing age, a symptom change has to be considered; disturbance of attention becomes more prominent, whereas hyperactivity often diminishes or changes to inactivity. Neuroimaging studies show a high striatal dopamine transporter (DAT) availability in most adults with ADHD; this can be reduced by stimulants. Nicotine seems to have a stimulant-like action on the DAT. In most adults with ADHD, therapy has to be multimodal, combining psychotherapy and medication. Methylphenidate is the first-line drug in adult ADHD; further options are amphetamine and noradrenaline reuptake inhibitors. Nonresponders to methylphenidate seem to have no elevated DAT availability prior to therapy. Combination with other psychiatric disorders occurs frequently in adults with ADHD; in these patients additional pharmacological treatment with special regard to the comorbid disease is recommended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular genetics of attention-deficit/hyperactivity disorder
Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.024 · Cited by 2,357
Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Castellanos, F. X., & Tannock, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn896 · Cited by 1,827
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Bush, G., Valera, E. M., & Seidman, L. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.034 · Cited by 714
Dopamine transporter density in patients with attention deficit hyperactivity disorder
Dougherty, D. D., Bonab, A. A., Spencer, T. J., Rauch, S. L., Madras, B. K., & Fischman, A. J. (1999) · The Lancet · doi:10.1016/s0140-6736(99)04030-1 · Cited by 684
Krause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., & Tatsch, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01040-5 · Cited by 521 · cited 1×
“The results obtained by our group showed not only the impairment of DAT but also reported for the first time in vivo and intraindividually in patients with ADHD, that impaired metabolism can be improved with methylphenidate: on administration of 5 mg 3 times daily it was seen that there was a clear reduction in DAT av…”
Self-citationGill, M., Daly, G., Heron, S., Hawi, Z., & Fitzgerald, M. (1997) · Molecular Psychiatry · doi:10.1038/sj.mp.4000290 · Cited by 482
Faraone, S. V., Spencer, T., Aleardi, M., Pagano, C., & Biederman, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000108984.11879.95 · Cited by 404
Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385
Dresel, S., Krause, J., Krause, K.-H., LaFougere, C., Brinkbäumer, K., Kung, H. F., Hahn, K., & Tatsch, K. (2000) · European Journal of Nuclear Medicine · doi:10.1007/s002590000330 · Cited by 278 · cited 1×
“The results obtained by our group showed not only the impairment of DAT but also reported for the first time in vivo and intraindividually in patients with ADHD, that impaired metabolism can be improved with methylphenidate: on administration of 5 mg 3 times daily it was seen that there was a clear reduction in DAT av…”
Self-citationCornish, K. M., Manly, T., Savage, R., Swanson, J., Morisano, D., Butler, N., Grant, C., Cross, G., Bentley, L., & Hollis, C. P. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001641 · Cited by 220
Court, J. A., Lloyd, S., Thomas, N., Piggott, M. A., Marshall, E. F., Morris, C. M., Lamb, H., Perry, R. H., Johnson, M., & Perry, E. K. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00088-8 · Cited by 135 · cited 4×
“Al parecer, la nicotina estimula el DAT.”
InfluentialKrause, K.-H., Dresel, S. H., Krause, J., Kung, H. F., Tatsch, K., & Ackenheil, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002821 · Cited by 88 · cited 1×
“Comparison of 11 smoking nonmedicated patients with ADHD with sex- and agematched nonsmoking drug-naive adults with ADHD showed significantly higher DAT density in the nonsmoking patients, despite higher ADHD scores for the smokers.(31) This finding suggests that nicotine may act directly on DAT in the same manner as…”
Self-citationKrause, J., la Fougere, C., Krause, K.-H., Ackenheil, M., & Dresel, S. H. (2005) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-005-0602-x · Cited by 84 · cited 1×
“Our initial results show that nonresponders to methylphenidate do not reveal raised DAT in striatum prior to therapy, whereas the responders seem to have a high DAT availability (Figure 4).(29) C l i n i c a l r e s e a r c h”
Self-citation
Cited by
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269
On the relation of mind wandering and ADHD symptomatology
Seli, P., Smallwood, J., Cheyne, J. A., & Smilek, D. (2015) · Psychonomic Bulletin & Review · doi:10.3758/s13423-014-0793-0 · Cited by 254
Attention-deficit-hyperactivity disorder and reward deficiency syndrome
Oscar Berman, M., Blum, K., Chen, T. J., Braverman, E., Waite, R., Downs, W., Arcuri, V., Notaro, A., Palomo, T., & Comings (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2627 · Cited by 248
“Dopamine D2 receptors, regional blood fl ow, and response to methylphenidate In reviews of published articles that examined striatal dopamine transporter (DAT) density in ADHD patients, Krause et al (2003; 2006) cited numerous neuroimaging fi ndings of elevation in that region.”
BackgroundDistinguishing comorbidity and successful management of adult ADHD
Kooij, J. J. S., Huss, M., Asherson, P., Akehurst, R., Beusterien, K., French, A., Sasané, R., & Hodgkins, P. (2012) · Journal of Attention Disorders · doi:10.1177/1087054711435361 · Cited by 172
Interaction of dopamine transporter genotype with prenatal smoke exposure on ADHD symptoms
Becker, K., El-Faddagh, M., Schmidt, M. H., Esser, G., & Laucht, M. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.07.004 · Cited by 142
Metadata
- Authors
- Krause, J., Krause, K.-H., Dresel, S. H., la Fougère, C., & Ackenheil, M.
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2006-03-31
- Volume
- 8
- Issue
- 1
- Pages
- 29-36
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- OpenAlex
- W2247959947
- Cited by
- 38
- References
- 14
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.